Skip to Main Content
 

Global Search Box

 
 
 
 

ETD Abstract Container

Abstract Header

COMMERCIALIZATION OF STEM CELL THERAPY FOR THE TREATMENT OF DIABETIC RETINOPATHY

Shanmugam, Shiva Prasad

Abstract Details

2010, Master of Sciences, Case Western Reserve University, Biology.
Diabetic Retinopathy is one of the leading causes of blindness or vision loss in working-age adults. Millions of adults over age forty are affected by the diseases and there exists an impending need for a safe and effective treatment. The purpose of this study is to demonstrate the scientific and market potential of a novel stem cell therapy being developed as an alternative treatment. The aim is to treat diabetic retinopathy through the process of therapeutic angiogenesis with ex vivo expanded stem cells transfected with VEGF-PDGF growth factors. This promotes the formation of fully functional blood vessels in the retina of the eye, and restores vision.
Chritopher Cullis, PhD (Committee Chair)
Jean Welter, PhD (Committee Member)
Ramasamy Sakthivel, PhD (Committee Member)
Robin Snyder, PhD (Committee Member)
65 p.

Recommended Citations

Citations

  • Shanmugam, S. P. (2010). COMMERCIALIZATION OF STEM CELL THERAPY FOR THE TREATMENT OF DIABETIC RETINOPATHY [Master's thesis, Case Western Reserve University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=case1278691262

    APA Style (7th edition)

  • Shanmugam, Shiva Prasad. COMMERCIALIZATION OF STEM CELL THERAPY FOR THE TREATMENT OF DIABETIC RETINOPATHY. 2010. Case Western Reserve University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=case1278691262.

    MLA Style (8th edition)

  • Shanmugam, Shiva Prasad. "COMMERCIALIZATION OF STEM CELL THERAPY FOR THE TREATMENT OF DIABETIC RETINOPATHY." Master's thesis, Case Western Reserve University, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=case1278691262

    Chicago Manual of Style (17th edition)